Literature DB >> 12708818

Therapy-related acute myelogenous leukaemia (t-AML) in a patient with multiple sclerosis treated with mitoxantrone.

C Heesen, M Bruegmann, J Gbdamosi, E Koch, A Mönch, C Buhmann.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 12708818     DOI： 10.1191/1352458503ms891xx

Source DB:  PubMed          Journal:  Mult Scler        ISSN： 1352-4585            Impact factor:   6.312


× No keyword cloud information.
  11 in total

Review 1.  Immunosuppressive agents in multiple sclerosis.

Authors:  Oliver Neuhaus; Bernd C Kieseier; Hans-Peter Hartung
Journal:  Neurotherapeutics       Date:  2007-10       Impact factor: 7.620

Review 2.  Evidence Report: The efficacy and safety of mitoxantrone (Novantrone) in the treatment of multiple sclerosis: Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology.

Authors:  James J Marriott; Janis M Miyasaki; Gary Gronseth; Paul W O'Connor
Journal:  Neurology       Date:  2010-05-04       Impact factor: 9.910

Review 3.  Acute myeloid leukemia developing in patients with autoimmune diseases.

Authors:  Safaa M Ramadan; Tamer M Fouad; Valentina Summa; Syed Kh Hasan; Francesco Lo-Coco
Journal:  Haematologica       Date:  2011-12-16       Impact factor: 9.941

4.  Mitoxantrone in worsening secondary progressive multiple sclerosis: A prospective, open-label study.

Authors:  Bhupendra O Khatri; Mary Wroblewski; John Kramer; Mary Dukic; Arleen Poplar; A J Anderson
Journal:  Curr Ther Res Clin Exp       Date:  2006-01

Review 5.  US FDA-approved disease-modifying treatments for multiple sclerosis: review of adverse effect profiles.

Authors:  Steven L Galetta; Clyde Markowitz
Journal:  CNS Drugs       Date:  2005       Impact factor: 5.749

Review 6.  Mitoxantrone: a review of its use in multiple sclerosis.

Authors:  Lesley J Scott; David P Figgitt
Journal:  CNS Drugs       Date:  2004       Impact factor: 5.749

Review 7.  [Mitoxanthrone in the therapy of multiple sclerosis].

Authors:  B C Kieseier; R Gold; H-P Hartung
Journal:  Nervenarzt       Date:  2003-10       Impact factor: 1.214

8.  Acute myeloid leukemia induced by mitoxantrone treatment for aggressive multiple sclerosis.

Authors:  Marco Capobianco; Simona Malucchi; Stefano Ulisciani; Carmen Fava; Giovanna Rege Cambrin; Luigina Avonto; Giuseppe Saglio; Antonio Bertolotto
Journal:  Neurol Sci       Date:  2008-07-09       Impact factor: 3.307

9.  Molecular analysis of t(15;17) genomic breakpoints in secondary acute promyelocytic leukemia arising after treatment of multiple sclerosis.

Authors:  Syed Khizer Hasan; Ashley N Mays; Tiziana Ottone; Antonio Ledda; Giorgio La Nasa; Chiara Cattaneo; Erika Borlenghi; Lorella Melillo; Enrico Montefusco; José Cervera; Christopher Stephen; Gnanam Satchi; Anne Lennard; Marta Libura; Jo Ann W Byl; Neil Osheroff; Sergio Amadori; Carolyn A Felix; Maria Teresa Voso; Wolfgang R Sperr; Jordi Esteve; Miguel A Sanz; David Grimwade; Francesco Lo-Coco
Journal:  Blood       Date:  2008-07-23       Impact factor: 22.113

10.  Results from the 5-year, phase IV RENEW (Registry to Evaluate Novantrone Effects in Worsening Multiple Sclerosis) study.

Authors:  Victor M Rivera; Douglas R Jeffery; Bianca Weinstock-Guttman; Daena Bock; Fernando Dangond
Journal:  BMC Neurol       Date:  2013-07-11       Impact factor: 2.474
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.